Study says drug development costs much less than previously estimated
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Data/Analytics
Shutterstock says men are ‘more responsive’ to online ads
Images that “mirror the demographic profile of their target audience” perform best, according to an eye-tracking study from picture provider Shutterstock.
Nearly every $100,000 drug approved in the last three years was for a rare disease
This includes Sarepta Therapeutics’ Exondys 5 and Vertex Pharmaceuticals’ Orkambi.
Infographic: The battle for medication adherence
Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.
Study: One-third of new drugs report safety issues
Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.
U.S. drug spend grew by 6% in 2016, the lowest rate in two years
This is likely due to fewer product launches and lower price increases.
Day 2 at Health Datapalooza
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
Day 1 at Health Datapalooza
HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.
Pharma R&D partnerships are on the rise: report
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
Off-label legal settlements do little to change prescribing patterns
An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.
Want to read more?
Please login or register first to view this content.
